The Food and Drug Administration gave Bayer HealthCare Animal Health Division the approval to market Veraflox Oral Suspension for cats, a veterinary prescription-only treatment of skin infections in cats caused by susceptible strains of Pasteurella multocida, Streptococcus canis, Staphylococcus aureus, Staphylococcus felis and Staphylococcus pseudintermedius.
Veraflox Oral Suspension is the first feline-only antibiotic formulation in its class to be approved by the FDA. It is the first third-generation fluoroquinolone approved for use by U.S. veterinarians.
“Veraflox Oral Suspension’s once- daily formulation is well accepted by cats and offers treatment convenience with an easy to use dispenser and dosing syringe that make dosing simple and precise,” Cristiano von Simson, DVM, MBA, director of Veterinary Technical Services at Bayer HealthCare LLC, Animal Health Division, North America, said.
The product has been used to treat over 310,00 cats in Europe since it was approved there in 2011, according to the company.
“Pradofloxacin, the active ingredient of Veraflox OS, is a new generation fluoroquinolone with high-activity dual molecular targeting of DNA replication,” von Simson said. “It was specifically developed to deliver an enhanced in vitro spectrum and potency. In addition to providing effective treatment, there is in vitro laboratory evidence to suggest that dual targeting may reduce the potential for the emergence of resistant bacterial strains.”